NICE Approves Durvalumab for Gastric Cancer Tre...

By HEOR Staff Writer

May 15, 2026

NICE has issued final draft guidance recommending durvalumab, within its marketing authorisation, for use with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by durvalumab ...
Bladder Cancer Treatment Impact: Barriers to Quality of Life in Patients
Global Growth and Challenges in Pharmacy Vaccination Training
Key Strategies in Neonatal Infection Management: Insights from NICE Guideline...
Merck Oncology Advancements Highlight Long-Term Data and Pipeline Progress at...
Strengthening Supply Chains: The EU Critical Medicines Act
Johnson & Johnson Advances Neuropsychiatry Treatment Innovations at APA ...
Marstacimab Cost-Effectiveness Analysis in Hemophilia Treatment: A Portuguese...
Breakthrough in Biocatalysis: Advancing Oral PCSK9 Inhibitors
Workshop on AI in GMP Manufacturing: Shaping Future Guidance from EMA
Dutch Elderly Care Challenges: Navigating Fragmentation in Support Systems
FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases
EUCOPE Pharmaceutical Regulation: Advocating for Innovative SMEs in a Changin...